GIST Trials

Trial Name

Subtype

Agents

Phase

Status

Sponsor

POLARIS-3: A Study of Olverembatinib in SDH-deficient GIST

Advanced GIST

Olverembatinib

III

Open, recruiting

Ascentage

Peak: CGT9486+Sunitinib vs. Sunitinib in GIST

Advanced GIST

CGT9486 (Bezuclastinib) and Sunitinib

III

Closed for recruitment, but active

Cogent Biosciences, Inc.

IDRX-42 in advanced GIST

Advanced GIST

IDRX-42

I

Open, recruiting

IDRx Inc

INSIGHT: Ripretinib vs. sunitinib

Advanced GIST

Ripretinib vs. Sunitinib

III

Open, recruiting

Deciphera Pharmaceuticals

INBRX-109 In Ewing Sarcoma and SDH-deficient GIST

DH-deficient GIST/ Ewing Sarcoma

INBRX-109

I

Open, recruiting

INHIBRX Inc.

SSG XXII: 3 vs. 5 years of adjuvant imatinib

Operable GIST

Imatinib

III

Closed for recruitment, but active

Scandinavian Sarcoma Group (SSG)